Engineering the human gut commensal Bacteroides thetaiotaomicron with synthetic biology

The role of the microbiome in health and disease is attracting the attention of researchers seeking to engineer microorganisms for diagnostic and therapeutic applications. Recent progress in synthetic biology may enable the dissection of host–microbiota interactions. Sophisticated genetic circuits that can sense, compute, memorize, and respond to signals have been developed for the stable commensal bacterium Bacteroides thetaiotaomicron, dominant in the human gut. In this review, we highlight recent advances in expanding the genetic toolkit for B. thetaiotaomicron and foresee several applications of this species for microbiome engineering. We provide our perspective on the challenges and future opportunities for the engineering of human gut-associated bacteria as living therapeutic agents.     

Analytical comparison of absolute quantification strategies to investigate the insulin signaling pathway in fat cells

So far, mass spectrometry-based targeted proteomics is the most sensitive approach to answer and address specific biological questions in an accurate and quantitative fashion. However, the data analysis design used for such quantification varies in the field leading to discrepancies in the reported values. In this study, different quantification strategies based on calibration curves were evaluated and compared. The best accuracy and coefficient of variation was achieved by ratio to ratio calibration curves. We applied the ratio to ratio quantification approach to analyze very low abundant insulin signaling proteins such as PIK3RA (0.10–0.93 fmol/μg), AKT1 (0.1–0.39 fmol/μg), and the insulin receptor (0.22–2.62 fmol/μg) in a fat cell model and demonstrated the adaptation of this pathway at different states of insulin sensitivity.     

总体国家安全观下合成生物学风险和应对策略研究*

合成生物学是近年来兴起的一门兼材料学、医学和信息学等学科特性的交叉学科,在促进医学进步和科技转化应用的同时,也在总体国家安全内涵中被赋予了特殊的重要地位。如何在新时期应对错综复杂的安全形势和严峻挑战,是世界各国和国际社会所面临的科技治理和生物安全的重要命题。重点介绍合成生物技术相关生物武器威胁、生物恐怖威胁、生物安全国际公约条例、生物安全伦理治理框架,总结近年来合成生物技术领域生物安全风险相关问题,提出合成生物学安全风险应对策略和国家总体安全观下科技发展建议。     

2017—2020年珠江口棘头梅童鱼的种群特征

为了掌握珠江口重要经济鱼类棘头梅童鱼的种群特征,根据2017—2020年春(3—4月)、秋(9—10月)两季在珠江口海域开展的底拖网调查及采集到的棘头梅童鱼样本,对其生物学特征和资源密度分布特征进行了初步分析。结果表明: 珠江口棘头梅童鱼体长、体重变化范围分别为22～168 mm、0.23～103.11 g,其中雌性个体的体长、体重均大于雄性个体,未见明显的小型化现象;性成熟体长集中在90～140 mm,未见性成熟提早现象。总体长体重关系式中的异速生长因子b值为2.9057,且年际变化小,而条件因子a值(3.029×10^-5)小于1988年该海域的调查结果,说明珠江口棘头梅童鱼整体生长发育良好,但栖息地环境质量(饵料供应、生长环境)下降。研究海域梅童鱼的开发率E为0.67,处于过度捕捞状态;梅童鱼资源密度平均值为77.73 kg·km^-2, 中西侧资源密度大于东侧,在纬度方向上总体分布均匀;根据4个资源密度高值区初步推测其产卵场在南沙港附近。2017—2020年的年平均资源密度比1980—1982年下降了93.5%,为持续利用该资源,建议条件成熟时可于春季在产卵场设立保护区,以保护补充群体与产卵群体。     

植物合成生物学领域发展态势的文献计量分析

合成生物学作为一种颠覆性技术可应用于农业领域的创新发展,解决当前农业学科中的瓶颈问题。利用文献计量学方法从领域发表论文的时序数量分布、主题分布等探测当前合成生物学的基本态势。基于领域的主题分布可知,其中植物合成生物学这一主题是稳定存在的且主题规模处于稳定增长趋势。聚焦植物合成生物学这一主题方向,在构建引文网络的基础上利用主路径分析方法从知识流动角度探测植物合成生物学领域重要知识节点,内容涵盖介子油苷生物合成途径,重要催化酶功能解析、转录因子的调控作用,组学方法的应用,利用微生物酵母进行生物物质合成,这些内容表征了合成生物的核心理论技术。     

基于层次分析法的旗舰物种遴选方法

旗舰物种是保护生物学中一个广泛应用的概念, 用于获得公众对保护行为的支持, 在生物多样性保护领域发挥着重要作用。但目前尚未见量化分析遴选和确定旗舰物种的公开报道, 致使学术界对旗舰物种的定义和使用相对主观, 缺乏科学依据。本文对旗舰物种的定义进行了梳理, 探讨了旗舰物种的内涵, 确定了旗舰物种的属性, 制定了遴选标准和量化遴选方法, 以便读者更好地理解和运用这一概念。目前旗舰物种的定义仍然局限在其社会学属性, 作者建议今后应加强其生物生态学属性。作者认为除了公众的关注度和认可度之外, 旗舰物种还应具备以下3个生态生物学和社会文化特征: (1)物种在当地的濒危程度及生存现状; (2)物种在当地生态系统中的重要性; (3)物种在当地民众中的影响力和认可度。基于此, 本文确定了表征旗舰物种社会文化属性和生态生物学属性的8个要素, 基于层次分析法提出了一种量化的旗舰物种遴选方法。该方法综合上述8个要素进行评判和计算分值, 以塔吉克斯坦境内分布的14种大型濒危哺乳动物的生态生物学属性和社会文化影响力为基础, 描述基于层次分析法遴选塔吉克斯坦哺乳类旗舰物种的方法和过程, 最终依据每个备选物种所得分值高低排序, 得到塔吉克斯坦旗舰物种的优先备选物种。本文首次提出了一种量化遴选旗舰物种的方法, 期望今后可基于该方法开发更加合理的旗舰物种遴选模型和算法。     

CelloSelect – A synthetic cellobiose metabolic pathway for selection of stable transgenic CHO cell lines

Current protocols for generating stable transgenic cell lines mostly rely on antibiotic selection or the use of specialized cell lines lacking an essential part of their metabolic machinery, but these approaches require working with either toxic chemicals or knockout cell lines, which can reduce productivity. Since most mammalian cells cannot utilize cellobiose, a disaccharide consisting of two β-1,4-linked glucose molecules, we designed an antibiotic-free selection system, CelloSelect, which consists of a selection cassette encoding Neurospora crassa cellodextrin transporter CDT1 and β-glucosidase GH1-1. When cultivated in glucose-free culture medium containing cellobiose, CelloSelect-transfected cells proliferate by metabolizing cellobiose as a primary energy source, and are protected from glucose starvation. We show that the combination of CelloSelect with a PiggyBac transposase-based integration strategy provides a platform for the swift and efficient generation of stable transgenic cell lines. Growth rate analysis of metabolically engineered cells in cellobiose medium confirmed the expansion of cells stably expressing high levels of a cargo fluorescent marker protein. We further validated this strategy by applying the CelloSelect system for stable integration of sequences encoding two biopharmaceutical proteins, erythropoietin and the monoclonal antibody rituximab, and confirmed that the proteins are efficiently produced in either cellobiose- or glucose-containing medium in suspension-adapted CHO cells cultured in chemically defined media. We believe coupling heterologous metabolic pathways additively to the endogenous metabolism of mammalian cells has the potential to complement or to replace current cell-line selection systems.     

Multiplex genome editing of mammalian cells for producing recombinant heparin

Heparin is an essential anticoagulant used for treating and preventing thrombosis. However, the complexity of heparin has hindered the development of a recombinant source, making its supply dependent on a vulnerable animal population. In nature, heparin is produced exclusively in mast cells, which are not suitable for commercial production, but mastocytoma cells are readily grown in culture and make heparan sulfate, a closely related glycosaminoglycan that lacks anticoagulant activity. Using gene expression profiling of mast cells as a guide, a multiplex genome engineering strategy was devised to produce heparan sulfate with high anticoagulant potency and to eliminate contaminating chondroitin sulfate from mastocytoma cells. The heparan sulfate purified from engineered cells grown in chemically defined medium has anticoagulant potency that exceeds porcine-derived heparin and confers anticoagulant activity to the blood of healthy mice. This work demonstrates the feasibility of producing recombinant heparin from mammalian cell culture as an alternative to animal sources.     

Combinatorial pathway engineering of Bacillus subtilis for production of structurally defined and homogeneous chitooligosaccharides

Chitooligosaccharides (COSs) have a widespread range of biological functions and an incredible potential for various pharmaceutical and agricultural applications. Although several physical, chemical, and biological techniques have been reported for COSs production, it is still a challenge to obtain structurally defined COSs with defined polymerization (DP) and acetylation patterns, which hampers the specific characterization and application of COSs. Herein, we achieved the de novo production of structurally defined COSs using combinatorial pathway engineering in Bacillus subtilis. Specifically, the COSs synthase NodC from Azorhizobium caulinodans was overexpressed in B. subtilis, leading to 30 ± 0.86 mg/L of chitin oligosaccharides (CTOSs), the homo-oligomers of N-acetylglucosamine (GlcNAc) with a well-defined DP lower than 6. Then introduction of a GlcNAc synthesis module to promote the supply of the sugar acceptor GlcNAc, reduced CTOSs production, which suggested that the activity of COSs synthase NodC and the supply of sugar donor UDP-GlcNAc may be the limiting steps for CTOSs synthesis. Therefore, 6 exogenous COSs synthase candidates were examined, and the nodCM from Mesorhizobium loti yielded the highest CTOSs titer of 560 ± 16 mg/L. Finally, both the de novo pathway and the salvage pathway of UDP-GlcNAc were engineered to further promote the biosynthesis of CTOSs. The titer of CTOSs in 3-L fed-batch bioreactor reached 4.82 ± 0.11 g/L (85.6% CTOS5, 7.5% CTOS4, 5.3% CTOS3 and 1.6% CTOS2), which was the highest ever reported. This is the first report proving the feasibility of the de novo production of structurally defined CTOSs by synthetic biology, and provides a good starting point for further engineering to achieve the commercial production.